TORONTO – Edmonton’s University of Alberta is lending its neuromotor research smarts to a wearable, machine learning driven sensors platform developed by Menlo Park, Calif., and Calgary, Alberta-based Protxx Inc. for better managing the future care of patients suffering from neurodegenerative conditions such as multiple sclerosis (MS).
Although details are yet to come, Equillium Inc.’s chief medical officer, Krishna Polu, told BioWorld that the company will move “urgently and expeditiously” to set up another experiment testing itolizumab in COVID-19 now that Bangalore, India-based partner Biocon Ltd. has unveiled positive phase II results with the CD6-targeting agent.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3D Medical, Apollo Med Innovations, Aytu Bioscience, Beroni Group, Biosig Technologies, Bruker, EfficacyAI, Forsitech, Health Catalyst, Healthfinch, Inscopix, Medmira, Quantzig, Standard Capital, Todos Medical, Webbdx.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Biontech, Clinigen, Cytodyn, Enzychem, Pfizer, Protokinetix.
RSS
